Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
262 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04750824 | Real-World Effectiveness of Afatinib (Gilotrif) Following Immunotherapy in the Treatment of Metastatic, Squamous Cell Carcinoma of the Lung: A Multi-Site Retrospective Chart Review Study in the U.S. | completed | — | 110 | Boehringer IngelheimINDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06370871 | Brightline-3: A Study to Find Out Whether Brigimadlin in Combination With Ezabenlimab Helps People With Advanced Soft Tissue Sarcoma | withdrawn | Phase 3 | 0 | Boehringer IngelheimINDUSTRY | 0 |
| Jul 17, 2024 |
| clinicaltrials |
| NCT02516553 | BI 894999 First in Human Dose Finding Study in Advanced Malignancies | completed | Phase 1 | 174 | Boehringer IngelheimINDUSTRY | 6 | Apr 15, 2024 | clinicaltrials |
| NCT03017885 | Post Marketing Surveillance of Nintedanib in Indian Patients With Non-small Cell Lung Cancer (NSCLC) After First-line Therapy | completed | — | 28 | Boehringer IngelheimINDUSTRY | 1 | Mar 25, 2024 | clinicaltrials |
| NCT02632721 | A Trial to Find and Investigate a Safe Dose of BI 836858 in Combination With Decitabine for Patients With Acute Myeloid Leukemia (AML) | completed | Phase 1 / Phase 2 | 49 | Boehringer IngelheimINDUSTRY | 4 | Mar 19, 2024 | clinicaltrials |
| NCT03604445 | This Study Aims to Find and Test a Safe Dose of BI 905677 in Patients With Different Types of Cancer (Solid Tumours) | terminated | Phase 1 | 37 | Boehringer IngelheimINDUSTRY | 4 | Mar 4, 2024 | clinicaltrials |
| NCT04147247 | A Trial to Find the Safe Dose for BI 905681 in Patients With Incurable Tumours or Tumours That Have Spread | completed | Phase 1 | 21 | Boehringer IngelheimINDUSTRY | 1 | Nov 29, 2023 | clinicaltrials |
| NCT02254005 | Single Dose Escalation Study of Bivatuzumab Mertansine in Female Patients With CD44v6 Positive Metastatic Breast Cancer | completed | Phase 1 | 24 | Boehringer IngelheimINDUSTRY | 0 | Oct 24, 2023 | clinicaltrials |
| NCT02254018 | Single Dose Escalation Study of Bivatuzumab Mertansine in Patients With Advanced Squamous Cell Carcinoma of the Head and Neck | completed | Phase 1 | 31 | Boehringer IngelheimINDUSTRY | 0 | Oct 24, 2023 | clinicaltrials |
| NCT02254031 | Dose Escalation of Bivatuzumab Mertansine in Female Patients With CD44v6 Positive Recurrent or Metastatic Breast Cancer | terminated | Phase 1 | 8 | Boehringer IngelheimINDUSTRY | 0 | Oct 24, 2023 | clinicaltrials |
| NCT00804856 | Phase I/IIa Trial to Investigate BI 6727 (Volasertib) as Monotherapy or in Combination With Cytarabine in Acute Myeloid Leukaemia | completed | Phase 2 | 180 | Boehringer IngelheimINDUSTRY | 7 | Oct 3, 2023 | clinicaltrials |
| NCT02273388 | BI 6727 Administered Intravenously Every 3 Weeks in Patients With Solid Tumours | completed | Phase 1 | 65 | Boehringer IngelheimINDUSTRY | 1 | Oct 3, 2023 | clinicaltrials |
| NCT01772563 | Investigation of Potential Drug-drug Interaction of Volasertib With Itraconazole in Patients With Various Tumours | completed | Phase 1 | 28 | Boehringer IngelheimINDUSTRY | 1 | Sep 1, 2023 | clinicaltrials |
| NCT01721876 | Volasertib in Combination With Low-dose Cytarabine in Patients Aged 65 Years and Above With Previously Untreated Acute Myeloid Leukaemia, Who Are Ineligible for Intensive Remission Induction Therapy (POLO-AML-2) | completed | Phase 3 | 666 | Boehringer IngelheimINDUSTRY | 25 | Feb 8, 2023 | clinicaltrials |
| NCT04835714 | A Study to Find a Safe and Effective Dose of BI 1701963 Alone and in Combination With BI 3011441 in Patients With Advanced Cancer and a Certain Mutation (Kirsten Rat Sarcoma Viral Oncogene Homologue [KRAS]) | terminated | Phase 1 | 8 | Boehringer IngelheimINDUSTRY | 1 | Feb 1, 2023 | clinicaltrials |
| NCT05107193 | Afatinib (GILOTRIF®) in Patients Suffering From Tumors Harboring Neuregulin 1 (NRG1) Gene Alterations (Specifically NRG1 Gene Fusion-positive Advanced Solid Tumors) | no longer available | — | — | Boehringer IngelheimINDUSTRY | 0 | Nov 8, 2022 | clinicaltrials |
| NCT00412880 | BI 2536 Second Line Monotherapy in SCLC | completed | Phase 2 | 23 | Boehringer IngelheimINDUSTRY | 2 | Jun 22, 2022 | clinicaltrials |
| NCT00376623 | Efficacy and Safety of BI 2536 in Advanced or Metastatic Non Small Cell Lung Cancer | completed | Phase 2 | 96 | Boehringer IngelheimINDUSTRY | 1 | Jun 21, 2022 | clinicaltrials |
| NCT04653142 | A Study to Test Different Doses of BI 765063 Alone and in Combination With BI 754091 in Japanese Patients With Different Types of Advanced Cancer (Solid Tumors) | completed | Phase 1 | 18 | Boehringer IngelheimINDUSTRY | 1 | May 10, 2022 | clinicaltrials |
| NCT00710710 | Open, Randomized Phase II Trial to Investigate the Efficacy and Safety of the PLK-1 Inhibitor BI 2536 in Patients With Advanced, Unresectable Pancreatic Cancer | completed | Phase 2 | 89 | Boehringer IngelheimINDUSTRY | 2 | May 4, 2022 | clinicaltrials |
| NCT02440854 | Evaluate the Impact of Afatinib on Quality of Life and Symptom Burden of Greek Subjects With Advanced NSCLC in Routine Patient Care Settings | completed | — | 80 | Boehringer IngelheimINDUSTRY | 1 | Apr 27, 2022 | clinicaltrials |
| NCT04627142 | A Study to Test Different Doses of BI 1701963 in Combination With Irinotecan in People With Advanced Bowel Cancer With Kirsten Rat Sarcoma Viral Oncogene Homologue (KRAS) Mutation | terminated | Phase 1 | 15 | Boehringer IngelheimINDUSTRY | 1 | Apr 20, 2022 | clinicaltrials |
| NCT02514239 | Phase I Dose Escalation of i.v. BI 836909 Monotherapy in Last Line Multiple Myeloma Patients | completed | Phase 1 | 43 | Boehringer IngelheimINDUSTRY | 2 | Feb 24, 2022 | clinicaltrials |
| NCT04499352 | A Study to Test BI 754091 Alone or in Combination With BI 836880 in People Who Have Advanced Anal Cancer | withdrawn | Phase 2 | 0 | Boehringer IngelheimINDUSTRY | 1 | Nov 15, 2021 | clinicaltrials |
| NCT01024920 | Compare Safety and Efficacy of BIBF 1120 Versus Sunitinib. | completed | Phase 2 | 99 | Boehringer IngelheimINDUSTRY | 5 | Jul 19, 2021 | clinicaltrials |
| NCT02372006 | Trial of Afatinib in Pediatric Tumours | completed | Phase 1 / Phase 2 | 56 | Boehringer IngelheimINDUSTRY | 12 | Mar 4, 2021 | clinicaltrials |
| NCT02285361 | GIOTRIF rPMS in Korean Patients With NSCLC | completed | — | 1,272 | Boehringer IngelheimINDUSTRY | 1 | Feb 24, 2021 | clinicaltrials |
| NCT03157089 | Testing Afatinib in Combination With Pembrolizumab in Patients With Squamous Cell Carcinoma of the Lung(LUX-Lung-IO) | completed | Phase 2 | 24 | Boehringer IngelheimINDUSTRY | 5 | Feb 23, 2021 | clinicaltrials |
| NCT02668393 | Nintedanib and Weekly Docetaxel in Lung Adenocarcinoma | completed | Phase 1 | 14 | Boehringer IngelheimINDUSTRY | 2 | Jan 29, 2021 | clinicaltrials |
| NCT03370770 | Afatinib Osimertinib Sequencing NIS | completed | — | 204 | Boehringer IngelheimINDUSTRY | 1 | Dec 24, 2020 | clinicaltrials |
| NCT02780687 | Afatinib Monotherapy in Patients With ERBB-deregulated Metastatic Urothelial Tract Carcinoma After Failure of Platinum Based Chemotherapy(LUX-Bladder 1) | completed | Phase 2 | 42 | Boehringer IngelheimINDUSTRY | 3 | Nov 18, 2020 | clinicaltrials |
| NCT02671422 | LUME BioNIS: a Biomarker Study in Patients With NSCLC | completed | — | 260 | Boehringer IngelheimINDUSTRY | 13 | Sep 24, 2020 | clinicaltrials |
| NCT01296932 | BI836826 Dose Escalation in Relapsed Chronic Lymphocytic Leukaemia (CLL) | completed | Phase 1 | 37 | Boehringer IngelheimINDUSTRY | 3 | Aug 20, 2020 | clinicaltrials |
| NCT01403948 | BI 836826 Dose Escalation in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) | completed | Phase 1 | 48 | Boehringer IngelheimINDUSTRY | 3 | Aug 11, 2020 | clinicaltrials |
| NCT01466660 | LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung | completed | Phase 2 | 319 | Boehringer IngelheimINDUSTRY | 14 | Apr 7, 2020 | clinicaltrials |
| NCT02514174 | Afatinib Treatment for Patients With EGFR Mutation Positive NSCLC Who Are Age 70 or Older | completed | Phase 4 | 25 | Boehringer IngelheimINDUSTRY | 1 | Mar 30, 2020 | clinicaltrials |
| NCT02272413 | Phase III Trial BI 695502 Plus Chemotherapy vs. Avastin® Plus Chemotherapy in Patients With Lung Cancer | completed | Phase 3 | 671 | Boehringer IngelheimINDUSTRY | 28 | Jan 13, 2020 | clinicaltrials |
| NCT02047903 | GIOTRIF in First Line Therapy of Advanced NSCLC With EGFR-mutations | completed | — | 161 | Boehringer IngelheimINDUSTRY | 1 | Jan 9, 2020 | clinicaltrials |
| NCT02776683 | Open-label, Single Arm Trial of BI 695502 in Patients With Previously Untreated Metastatic Colorectal Cancer(INVICTAN®-3) | completed | Phase 3 | 123 | Boehringer IngelheimINDUSTRY | 4 | Nov 21, 2019 | clinicaltrials |
| NCT01953913 | Afatinib (BIBW 2992) in Advanced Non-Small Cell Lung Cancer Patients With EGFR Mutation | completed | Phase 3 | 542 | Boehringer IngelheimINDUSTRY | 5 | Aug 12, 2019 | clinicaltrials |
| NCT02751879 | Real World Data on Gi(l)Otrif® Dose Adjustment | completed | — | 228 | Boehringer IngelheimINDUSTRY | 13 | Aug 8, 2019 | clinicaltrials |
| NCT00969553 | Dose Finding Study of BI 6727 (Volasertib) in Patients With Various Solid Cancers | completed | Phase 1 | 59 | Boehringer IngelheimINDUSTRY | 1 | Jul 26, 2019 | clinicaltrials |
| NCT01125566 | LUX-Breast 1: BIBW 2992 (Afatinib) in HER2-positive Metastatic Breast Cancer Patients After One Prior Herceptin Treatment | completed | Phase 3 | 508 | Boehringer IngelheimINDUSTRY | 38 | Jul 18, 2019 | clinicaltrials |
| NCT01271725 | LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment Failures | completed | Phase 2 | 74 | Boehringer IngelheimINDUSTRY | 6 | Jun 17, 2019 | clinicaltrials |
| NCT02624492 | To Determine the Dose of BI 836826-GemOx and the Efficacy of BI 836826-GemOx Versus R-GemOx in Patients With Relapsed/Refractory DLBCL | completed | Phase 2 | 21 | Boehringer IngelheimINDUSTRY | 3 | Jun 17, 2019 | clinicaltrials |
| NCT01907100 | Nintedanib (BIBF 1120) in Mesothelioma | terminated | Phase 2 / Phase 3 | 545 | Boehringer IngelheimINDUSTRY | 27 | Mar 18, 2019 | clinicaltrials |
| NCT02751385 | Investigation of the Effect of Nintedanib on the Pharmacokinetics of a Combination of Ethinylestradiol and Levonorgestrel in Patients With Non-small Cell Lung Cancer | terminated | Phase 1 | 2 | Boehringer IngelheimINDUSTRY | 1 | Mar 14, 2019 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials